Chloroarenes

BIOLASE and EdgeEndo Announce Plans to Develop New EdgePRO Laser-Assisted Microfluidic Irrigation Device for Endodontists

Retrieved on: 
Tuesday, April 20, 2021
Chemistry, Physical sciences, Chemical substances, Antiseptics, Disinfectants, Oxidizing agents, Chlorhexidine, Chloroarenes, Oral hygiene, Enterococcus faecalis, Endodontics, Sodium hypochlorite

This new Microfluidic Irrigation device is being developed to offer a solution for endodontists seeking more from their current cleaning and disinfection techniques, such as sodium hypochlorite, ethylenediaminetetraacetic acid, chlorhexidine or 2-in-1 or 3-in-1 irrigation solutions.

Key Points: 
  • This new Microfluidic Irrigation device is being developed to offer a solution for endodontists seeking more from their current cleaning and disinfection techniques, such as sodium hypochlorite, ethylenediaminetetraacetic acid, chlorhexidine or 2-in-1 or 3-in-1 irrigation solutions.
  • BIOLASE anticipates submitting a premarket notification (510(k)) to the Food and Drug Administration for the co-developed device in the second quarter of 2021.
  • This announcement comes on the heels of the recently developed Waterlase Endo Academy , open to all Waterlase endodontists.
  • Juric IB, Plecko V, Anic I. Antimicrobial Efficacy of Er,Cr:YSGG Laser-Activated Irrigation Compared with Passive Ultrasonic Irrigation and RinsEndo((R)) Against Intracanal Enterococcus faecalis.

Neurelis Announces Five Poster Presentations for the Annual Meeting of the American Academy Of Neurology

Retrieved on: 
Monday, April 19, 2021
Drugs, GABAA receptor positive allosteric modulators, Chloroarenes, Lactams, Benzodiazepines, Anxiolytics, Clinical medicine, Psychoactive drugs, Diazepam, Seizure, Neonatal seizure, Lacosamide

In addition, the data shows that patients reported feeling like their usual self within two hours after VALTOCO administration.

Key Points: 
  • In addition, the data shows that patients reported feeling like their usual self within two hours after VALTOCO administration.
  • To be able to continue on with your day is very meaningful for patients with seizure clusters.
  • In a long-term, open-label, repeat-dose clinical trial, the safety of VALTOCO was evaluated, and more than 4,000 seizures were treated.
  • Serious and fatal adverse reactions, including "gasping syndrome", can occur in neonates and low-birth-weight infants treated with benzyl alcohol-preserved drugs, including VALTOCO.

Arcus Biosciences Presents Updated Data for Etrumadenant in Third-Line Metastatic Colorectal Cancer and New Data on its HIF-2α Program at the AACR 2021 Annual Meeting

Retrieved on: 
Saturday, April 10, 2021
Biotechnology, Hospitals, Health, Pharmaceutical, Oncology, Organic compounds, Chemical compounds, Chemistry, Chloroarenes, Pyridines, Regorafenib, Ureas, Tipiracil, Progression-free survival, Cancer, Etrumadenant, Arcus Biosciences

Efficacy Results (n=22 efficacy-evaluable 3L+ patients as of the DCO of Feb. 26, 2021)

Key Points: 
  • Efficacy Results (n=22 efficacy-evaluable 3L+ patients as of the DCO of Feb. 26, 2021)
    Median progression-free survival (PFS) of 4.2 months.
  • Reported data for current standard-of-care (SOC) therapies have shown a median PFS of 2.0 and 1.9 months for trifluridine-tipiracil and regorafenib, respectively3,4.
  • Reported data for trifluridine-tipiracil and regorafenib have shown a median OS of 7.1 and 6.4 months, respectively3,4.
  • Few options exist today to treat third-line colorectal cancer, and these therapies are associated with significant toxicity and limited efficacy.

Cosmos Holdings Launches Mosept-Oral Antiseptic Spray Designed to be Effective Against Bacteria and Certain Viral Pathogens

Retrieved on: 
Thursday, April 8, 2021
Biocides, Antiseptics, Antimicrobials, Biguanides, Microbiology, Bactericides, Disinfectants, Chlorhexidine, Chloroarenes, Bactericide, Bacteriostatic agent, Bisbiguanide

The Company has also started the registration process for Mosept-Oral for the UK with the submission of the documentation for the formulation.

Key Points: 
  • The Company has also started the registration process for Mosept-Oral for the UK with the submission of the documentation for the formulation.
  • Initial target countries are the United Kingdom, Germany, the Netherlands, France, Italy, Spain, Cyprus, Canada and the Middle East.
  • The mouth spray was formulated, designed and developed entirely by the Cosmos Holdings research and development team.
  • Chlorhexidine is a bisbiguanide antiseptic and disinfectant which is bactericidal or bacteriostatic against a wide range of Gram-positive and Gram-negative bacteria and inhibits the proliferation of certain viruses and fungi.

Hyundai Bioscience leads in the repurposing of Niclosamide

Retrieved on: 
Thursday, April 8, 2021
Anthelmintics, Chloroarenes, Salicylanilides, Niclosamide, Nitrobenzenes, Pesticides, Hyundai Motor Company, Drug repositioning, Repurposing, Articles, Drugs, Health sciences

CNPharm also filed international patent applications on this DDS technology for repurposing Niclosamide as COVID-19 treatment.

Key Points: 
  • CNPharm also filed international patent applications on this DDS technology for repurposing Niclosamide as COVID-19 treatment.
  • This means that the international pharmaceutical community has recognized that CNPharm, the parent company of Hyundai Bioscience, is leading the way to repurpose the anthelmintic drug.
  • An official at Hyundai Bioscience stated that this is the first time that Niclosamide's bioavailability improvement for drug repurposing has been published in an international journal.
  • Based on CNPharm's original technology, Hyundai Bioscience has dramatically improved the absorption rate and half-life of Niclosamide last year, developing CP-COV03, an oral treatment for COVID-19.

Evoke Pharma Receives Notice of Allowance from United States Patent and Trademark Office for a Method of Use Patent with Claims Covering Gimoti®

Retrieved on: 
Tuesday, April 6, 2021
Digestive diseases, Clinical medicine, Medical specialties, Chloroarenes, Antiemetics, Prolactin releasers, Dosage forms, Metoclopramide, Gastroparesis, Nasal spray

When granted, the patent will cover methods of use for nasal delivery of metoclopramide for the treatment of gastroparesis.

Key Points: 
  • When granted, the patent will cover methods of use for nasal delivery of metoclopramide for the treatment of gastroparesis.
  • The patent, entitled Nasal Formulations of Metoclopramide, carries a patent term to at least 2029.
  • Gimoti is Evokes nasal spray product for the relief of symptoms in acute and recurrent diabetic gastroparesis.
  • This new patent covers Gimoti for gastroparesis and will be listable in FDAs Orange Book.

AzurRx BioPharma Initiates Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

Retrieved on: 
Tuesday, April 6, 2021
Anthelmintics, Chloroarenes, Niclosamide, Nitrobenzenes, Pesticides, Salicylanilides, Severe acute respiratory syndrome coronavirus, COVID-19, Health, Medical specialties

These long term observation data could indicate that niclosamide treatment has the potential to improve long haul COVID-19 symptoms.

Key Points: 
  • These long term observation data could indicate that niclosamide treatment has the potential to improve long haul COVID-19 symptoms.
  • We look forward to testing this hypothesis in the RESERVOIR Phase 2 trial and reporting topline data from the trial in early 2022.
  • FW-1022 is a niclosamide based small molecule which the Companys clinical trials may establish has anti-viral activity that is effective for the treatment of SARS-CoV-2 (COVID-19) gastrointestinal infections.
  • AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.

New England Journal of Medicine Publishes Results of the PULSAR Phase 2 Trial of Sotatercept in Patients with Pulmonary Arterial Hypertension

Retrieved on: 
Thursday, April 1, 2021
Research, Infectious diseases, Clinical trials, Cardiology, Biotechnology, Health, Pharmaceutical, Other Science, Science, Hypertension, Pulmonary hypertension, Placebo-controlled study, Chemical compounds, PAH, Medical research, Chloroarenes, Organic compounds, Riociguat, the PULSAR Trial, Sotatercept, PAH, Acceleron

This is a result that suggests that sotatercept could bring an important new mechanistic approach to the treatment of patients with PAH.

Key Points: 
  • This is a result that suggests that sotatercept could bring an important new mechanistic approach to the treatment of patients with PAH.
  • The PULSAR publication marks the third time that trial results of an Acceleron-discovered therapy have been published in the New England Journal of Medicine in the past 15 months.
  • The PULSAR Phase 2 trial is a randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of sotatercept in patients with PAH.
  • In pulmonary, Acceleron is developing sotatercept for the treatment of pulmonary arterial hypertension (PAH), having reported positive topline results of the PULSAR Phase 2 trial.

DGAP-News: Newron announces results of explanatory studies with evenamide in healthy volunteers and patients with schizophrenia

Retrieved on: 
Thursday, April 1, 2021
Psychiatry, Receptor antagonists, Branches of biology, Psychopathology, Dopamine antagonists, Schizophrenia, Atypical antipsychotics, Chloroarenes, Antipsychotic, Psychosis, QT interval, Management of schizophrenia, evenamide, Newron Pharmaceuticals

These results strongly suggest that evenamide does not increase a patient's risk of QTc prolongation and arrhythmias, a risk generally associated with antipsychotics.

Key Points: 
  • These results strongly suggest that evenamide does not increase a patient's risk of QTc prolongation and arrhythmias, a risk generally associated with antipsychotics.
  • No patient on evenamide discontinued from the study due to adverse events, and there were no significant adverse events relating to evenamide.
  • Evenamide has the potential to be first add-on therapy for the treatment of patients with positive symptoms of schizophrenia.
  • Newron is also developing evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia.

Apotex Corp. Issues Voluntary Nationwide Recall of Guanfacine Extended-Release Tablets 2mg due to trace amounts of Quetiapine Fumarate

Retrieved on: 
Wednesday, March 31, 2021
Merchandising, Articles, Marketing, Economy, Acetamides, Chloroarenes, Guanfacine, Distribution, Apotex, Wholesaling, Online shopping, Pharmacy

The three (3) affected lots of Guanfacine extended-release tablets were distributed by Apotex nationwide in the USA to Wholesalers, Distributors, Warehousing Chains, Independent Retail Pharmacy and Retail Buying Group.

Key Points: 
  • The three (3) affected lots of Guanfacine extended-release tablets were distributed by Apotex nationwide in the USA to Wholesalers, Distributors, Warehousing Chains, Independent Retail Pharmacy and Retail Buying Group.
  • Patients who have received either of the three impacted lots of Guanfacine Extended-Release Tablets or have questions regarding this recall should contact their pharmacy.
  • Wholesalers, Distributors, Warehousing Chains, Independent Retail Pharmacy and Retail Buying Group should return the recalled product to the place of purchase.
  • Consumers with questions regarding this recall can contact Apotex Corp. by phone at 1-800-706-5575 (8:30am 5:00pm, EST Monday thru Friday) or email address [email protected] .